NEW YORK – Cancer genetics testing lab firm NeoGenomics said on Wednesday that it has acquired Trapelo Health for $65 million, consisting of $35 million in cash on hand and $30 million in NeoGenomics' common stock.
Fort Myers, Florida-based NeoGenomics will offer Burlington, Massachusetts-based Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.